Prosecution Insights
Last updated: July 17, 2026
Application No. 18/254,319

USE OF ZANAMIVIR IN PREPARATION OF DRUG FOR TREATING OR PREVENTING PREECLAMPSIA

Non-Final OA §112
Filed
May 24, 2023
Priority
Nov 24, 2020 — CN 2020113317829 +3 more
Examiner
SHTERENGARTS, SAMANTHA L
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shenzhen Evergreen Therapeutics Co. Ltd.
OA Round
2 (Non-Final)
79%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
1337 granted / 1685 resolved
+19.3% vs TC avg
Moderate +8% lift
Without
With
+8.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
67 currently pending
Career history
1722
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
18.5%
-21.5% vs TC avg
§102
24.0%
-16.0% vs TC avg
§112
22.3%
-17.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1685 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on May 21, 2026 has been entered. Information Disclosure Statement 3. The information disclosure statement (IDS) submitted on May 21, 2026 was in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The IDS document was considered. A signed copy of form 1449 is enclosed herewith. Status of Claims 4. Claims 5-9, 15, and 18 are pending and under consideration in the instant application. Claim Rejections - 35 USC § 112 5. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. 6. Claim 9 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 9 contains the limitation “wherein said treating PNG media_image1.png 94 512 media_image1.png Greyscale ” which falls outside the scope of Claim 5, from which claim 9 depends. Claim 5 is drawn to the same method, with limitation as follows: “wherein said PNG media_image2.png 49 523 media_image2.png Greyscale . As such, claim 9 falls outside the scope of claim 5. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion 7. Claims 5-8, 15, and 18 are allowed. 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samantha Shterengarts whose telephone number is (571)270-5316. The examiner can normally be reached on Monday thru Thursday 9-6pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mr. Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAMANTHA L SHTERENGARTS/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

May 24, 2023
Application Filed
Jan 12, 2024
Response after Non-Final Action
Aug 29, 2025
Non-Final Rejection mailed — §112
Dec 01, 2025
Response Filed
May 21, 2026
Request for Continued Examination
May 26, 2026
Response after Non-Final Action
Jun 12, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679837
AMINOPYRIMIDINE COMPOUND AS CDK2/4/6 TRIPLE INHIBITOR
4y 3m to grant Granted Jul 14, 2026
Patent 12679852
METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 3-(2-CHLOROTHIAZOL-5-YL)-8-METHYL-7-OXO-6-PHENYL-2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM-5-OLATE
2y 12m to grant Granted Jul 14, 2026
Patent 12673917
NEW BISPHENOLS BEARING PENDANT CLICKABLE NORBORNENYL GROUP AND POLYMERS THEREFROM
3y 0m to grant Granted Jul 07, 2026
Patent 12673050
Compositions and their Use for the Treatment of A1-Antitrypsin Deficiency
2y 6m to grant Granted Jul 07, 2026
Patent 12673939
METHODS OF SYNTHESIS OF HETEROARYL DERIVATIVES OF TRIAZOLYL ACRYLAMIDES AND CRYSTALLINE FORMS
2y 7m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
79%
Grant Probability
87%
With Interview (+8.0%)
2y 1m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1685 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month